Momelotinib expands the therapeutic armamentarium for myelofibrosis: Impact on hierarchy of treatment choices
American Journal of Hematology · 2024
DOI: 10.1002/ajh.27163 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Hematology, 2024. Verfasst von Ayalew Tefferi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Primary Myelofibrosis, Anemia, Benzamides, Bridged-Ring Compounds. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 78 Literaturangaben.
Abstract (Originalsprache)
The primary objective of treatment in myelofibrosis (MF) is prolongation of life, which is currently accomplished only by allogeneic hematopoietic stem cell transplantation (AHSCT). Determination of optimal timing for AHSCT is facilitated by molecular risk stratification. Non‐transplant treatment options in MF are palliative in scope and include Janus kinase 2 (JAK2) inhibitors (JAKi): momelotinib (FDA approved on September 15, 2023), ruxolitinib (November 16, 2011), fedratinib (August 16, 2019), and pacritinib (February 28, 2022); all four JAKi are effective in reducing spleen size and alleviating symptoms, considered a drug class effect and attributed to their canonical JAK–STAT inhibitory mechanism of action. In addition, momelotinib exhibits erythropoietic effect, attributed to alleviation of ineffective erythropoiesis through inhibition of activin A receptor type‐I (ACVR1). In transplant‐ineligible or deferred patients, the order of treatment preference is based on specific symptoms and individual assessment of risk tolerance. Because of drug‐induced immunosuppression and other toxicities attributed to JAKi, we prefer non‐JAKi drugs as initial treatment for MF‐associated anemia that is not accompanied by treatment‐requiring splenomegaly or constitutional symptoms. Otherwise, it is reasonable to consider momelotinib as the first‐line JAKi treatment of choice, in order to target the triad of quality‐of‐life offenders in MF: anemia, splenomegaly, and constitutional symptoms/cachexia. For second‐line therapy, we favor ruxolitinib, over fedratinib, based on toxicity profile. Pacritinib and fedratinib provide alternative options in the presence of severe thrombocytopenia or ruxolitinib‐resistance/intolerance, respectively. Splenectomy remains a viable option for drug‐resistant symptomatic splenomegaly and cytopenia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
ORCID-Profile: Ayalew Tefferi, Animesh Pardanani, Naseema Gangat
Zitieren
APA
Tefferi, A., Pardanani, A., & Gangat, N. (2024). Momelotinib expands the therapeutic armamentarium for myelofibrosis: Impact on hierarchy of treatment choices. American Journal of Hematology. https://doi.org/10.1002/ajh.27163
Vancouver
Tefferi A, Pardanani A, Gangat N. Momelotinib expands the therapeutic armamentarium for myelofibrosis: Impact on hierarchy of treatment choices. American Journal of Hematology. 2024. doi:10.1002/ajh.27163
BibTeX
@article{Tefferi2024,
author = {Tefferi, Ayalew and Pardanani, Animesh and Gangat, Naseema},
title = {Momelotinib expands the therapeutic armamentarium for myelofibrosis: Impact on hierarchy of treatment choices},
journal = {American Journal of Hematology},
year = {2024},
doi = {10.1002/ajh.27163}
}
EUVIMED